Hospital
Pontotoc Health Services, INC.
Pontotoc Health Services, INC. was paid $11.55M by Medicaid between Jan 2018 and Dec 2024, across 115 billing codes. Its largest line is 99284, emergency room visit (serious) — 27% of everything it billed.
33Billing provider infoPONTOTOC HEALTH SERVICES, INC.
PONTOTOC, MS 38863
PONTOTOC, MS 38863
33aNPI1821103516assigned 08/20/2006
33bProvider typeCritical Access Hospital
28Total paid$11.55M
24GClaims200,531
24DCodes billed115
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Mississippi
Rank by total paid#4 of 32
Median peer was paid$3.94M
This provider vs. median2.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TOPPIN, BRUCE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,103 | $1.49M | |
| 2019 | 26,864 | $1.90M | |
| 2020 | 24,469 | $1.45M | |
| 2021 | 24,894 | $1.54M | |
| 2022 | 29,280 | $1.70M | |
| 2023 | 39,684 | $1.99M | |
| 2024incomplete | 31,237 | $1.48M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 27% | 14,794 | 11,782 | $3.15M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 12,868 | 9,705 | $1.70M |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 13% | 11,364 | 1,557 | $1.50M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.0% | 3,165 | 2,678 | $928K |
| 87428 | 3.5% | 7,906 | 6,786 | $401K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.3% | 3,153 | 2,774 | $377K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.4% | 5,588 | 1,419 | $278K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 2,428 | 2,168 | $276K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.3% | 5,752 | 4,798 | $264K |
| 71045 | Radiologic examination, chest; single view | 2.2% | 5,167 | 4,451 | $257K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 5,464 | 1,091 | $239K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 753 | 675 | $237K |
103 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 3,156 | $195K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 2,811 | $138K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.2% | 1,161 | $133K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 4,065 | $126K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 1,023 | $123K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 446 | $119K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,661 | $109K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,098 | $102K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,255 | $81K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,455 | $81K |
| 80053 | Comprehensive metabolic panel | <1% | 9,775 | $74K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 358 | $59K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,462 | $54K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 879 | $49K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,724 | $46K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,896 | $31K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,262 | $27K |
| 80061 | Lipid panel | <1% | 2,502 | $27K |
| 83880 | <1% | 1,194 | $26K | |
| 84484 | <1% | 3,339 | $26K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 322 | $25K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,529 | $23K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,535 | $21K |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,840 | $14K |
| 87081 | <1% | 2,484 | $14K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 104 | $14K |
| 87807 | <1% | 1,267 | $13K | |
| 83690 | <1% | 2,317 | $11K | |
| 81001 | <1% | 4,193 | $11K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 537 | $10K |
| 87040 | <1% | 1,513 | $10K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,684 | $9K |
| 81025 | <1% | 1,153 | $8K | |
| 73630 | <1% | 162 | $8K | |
| 80076 | <1% | 1,083 | $7K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,467 | $6K |
| 82728 | <1% | 677 | $6K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,651 | $5K |
| 73030 | <1% | 89 | $5K | |
| 81003 | <1% | 2,403 | $5K | |
| Q3014 | Telehealth originating site facility fee | <1% | 352 | $5K |
| 87077 | <1% | 775 | $4K | |
| 87186 | <1% | 748 | $4K | |
| 82607 | <1% | 446 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,959 | $4K |
| 83605 | <1% | 669 | $4K | |
| 83735 | <1% | 940 | $4K | |
| 73562 | <1% | 75 | $3K | |
| 83550 | <1% | 582 | $3K | |
| 84703 | <1% | 587 | $3K | |
| 85027 | <1% | 542 | $3K | |
| 83540 | <1% | 701 | $3K | |
| 74018 | <1% | 67 | $3K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 45 | $3K |
| 96376 | <1% | 220 | $3K | |
| 72100 | <1% | 46 | $3K | |
| 97161 | <1% | 15 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 34 | $2K |
| 73610 | <1% | 46 | $2K | |
| 87400 | <1% | 82 | $2K | |
| 80305 | <1% | 129 | $1K | |
| 92526 | <1% | 33 | $1K | |
| 85610 | <1% | 587 | $1K | |
| 86140 | <1% | 329 | $1K | |
| A9270 | Non-covered item or service | <1% | 1,518 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 46 | $1K |
| 82550 | <1% | 187 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 796 | $1K |
| 82553 | <1% | 102 | $987.65 | |
| 97165 | <1% | 29 | $962.92 | |
| 85379 | <1% | 91 | $774.08 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,190 | $702.81 |
| 82962 | <1% | 258 | $582.39 | |
| 82570 | <1% | 69 | $534.94 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 14 | $519.01 |
| 82044 | <1% | 35 | $381.47 | |
| 86308 | <1% | 57 | $359.61 | |
| 73502 | <1% | 16 | $332.70 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $316.76 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12 | $316.76 |
| 82948 | <1% | 79 | $295.10 | |
| 99305 | <1% | 12 | $271.04 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 357 | $262.36 |
| 86738 | <1% | 21 | $254.41 | |
| 90715 | <1% | 46 | $237.34 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,064 | $209.17 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 304 | $203.61 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 77 | $176.08 |
| 99307 | <1% | 23 | $157.89 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 109 | $151.16 |
| 82150 | <1% | 32 | $129.95 | |
| 84145 | <1% | 377 | $126.11 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 126 | $103.66 |
| 83615 | <1% | 19 | $76.21 | |
| 82043 | <1% | 17 | $59.42 | |
| 85652 | <1% | 27 | $43.84 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 35 | $43.40 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 22 | $7.75 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 37 | $4.48 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 92 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 66 | $0.00 |
| 36416 | 0% | 198 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTOPPIN, BRUCE (CORPORATE SECRETARY)
Parent organizationPONTOTOC HEALTH SERVICES, INC.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.